Morteza Nadjafi, MD
Psychiatry · Orlando, FLNPI 1912954660
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,593 of the $57,634 with a category attached, or 61.8%. Johnson & Johnson accounts for 72.0% of it on its own, with 40 other manufacturers making up the rest. Reporting peaked in 2019 at $40,822 and has fallen 90.5% since, to $3,890 in 2025. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 543 payments — averaging $106.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$41K
- Neurocrine Biosciences, Inc.$3K
- Brainsway USA Inc$1K
- AbbVie$1K
- Pfizer$1K
- Roche Products Limited$1K
- plus $9K from 35 others
Across 1,145 payments — averaging $4584.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.4M
- AbbVie$574K
- Acadia Pharmaceuticals Inc$534K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$527K
- Genentech, Inc.$517K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$444K
- plus $1.3M from 15 others
What the payments were for
- Consulting fees$7501%
- Speaking & faculty fees$35,59362%
- Travel & lodging$7,99314%
- Food & beverage$13,20223%
- Education$820%
- Gifts$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$39,926
- Brainsway Deep TMS$1,443
- GEODON$1,161
- Equetro$321
- INGREZZA$264
- AUSTEDO$253
- VRAYLAR$248
- COBENFY$247
- Quillichew ER$124
- Dyanavel XR$124
- Quillivant$124
- Cotempla XR-ODT$120
- Adzenys XR-ODT$120
- ZolpiMist$120
- NUPLAZID$112
- VNS - Symmetry$110
How this compares
$57,634 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 20 | $199,169 |
| RexultiBrexpiprazole | 13 | $18,226 |
| Clozapine | 61 | $6,225 |
| Ziprasidone Hcl | 46 | $5,522 |
| Lurasidone Hcl | 18 | $3,291 |
| Fluphenazine Hcl | 12 | $2,308 |
| Haloperidol Decanoate | 28 | $1,930 |
| Imipramine Hcl | 16 | $1,781 |
| Aripiprazole | 47 | $1,559 |
| Haloperidol | 36 | $1,444 |
| Trazodone Hcl | 77 | $1,407 |
| Clonazepam | 120 | $1,250 |
| Bupropion XlBupropion Hcl | 46 | $1,107 |
| LoxapineLoxapine Succinate | 12 | $1,062 |
| Olanzapine | 35 | $1,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $2,695 | $199,16920 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $404 | $18,22613 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $438 | $1,06212 claims |
| Almatica Pharma LLCSertraline Hcl | $161 | $40250 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Orlando
- Ramon MartinezOrlando$354K
- David MedinaOrlando$199K
- Carlos RuizOrlando$104K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.